Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: A systematic review.

Khalili, Neda; Keshavarz-Fathi, Mahsa; Shahkarami, Sepideh; Hirbod-Mobarakeh, Armin; Rezaei, Nima

Khalili, Neda; Keshavarz-Fathi, Mahsa; Shahkarami, Sepideh; Hirbod-Mobarakeh, Armin; Rezaei, Nima.

Afiliación

Khalili N; 1 Border of Immune Tolerance Education and Research Network (BITERN), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Keshavarz-Fathi M; 2 School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Shahkarami S; 2 School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Hirbod-Mobarakeh A; 3 Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Rezaei N; 4 Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

J Oncol Pharm Pract ; 25(4): 903-917, 2019 Jun.

Article en En | MEDLINE | ID: mdl-30348069

Asunto(s)

Anticuerpos Monoclonales/uso terapéutico; Antineoplásicos Inmunológicos/uso terapéutico; Neoplasias de la Próstata/tratamiento farmacológico; Antígenos de Superficie/sangre; Glutamato Carboxipeptidasa II/sangre; Humanos; Inmunoterapia/métodos; Calicreínas/sangre; Masculino; Antígeno Prostático Específico/sangre; Neoplasias de la Próstata/sangre

Palabras clave

Passive-specific immunotherapy; monoclonal antibodies; neoplasm; prostate cancer; prostate stem cell antigen; prostate-specific membrane antigen

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antineoplásicos Inmunológicos / Anticuerpos Monoclonales Tipo de estudio: Guideline / Systematic_reviews Límite: Humans / Male Idioma: En Revista: J Oncol Pharm Pract Asunto de la revista: FARMACIA Año: 2019 Tipo del documento: Article País de afiliación: Irán

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google